VYNE Therapeutics Inc (VYNE)

[BiotechValues]

$MNLO looking at $250 million-plus in peak sales per Cowen in this article out today. Don't believe this includes any potential sales in China from last week's pr.

“…our clinicians continue to highlight their even greater enthusiasm for FMX-103, given that rosacea – although a smaller overall market than acne – has very limited treatment options. Taking the likely lower penetration of Amzeeq into the massive acne market, combined with the likely high penetration of FMX-103 into the smaller rosacea market, we continue to believe that these opportunities could eventually each exceed $250 million-plus in peak sales, which is clearly not reflected in the current valuation.”


“the launch was progressing as well as – and if not better – than any recent launch in acne.” Total prescriptions hit the 2,150 mark for the week ending March 13, indicating a revenue run-rate of about $20-$25 million.


https://blog.tipranks.com/3-biotech-stocks-under-4-with-big-upside-potential/